First Line Persistence (PSM)
Total Page：16
File Type：pdf, Size：1020Kb
First Line Persistence (PSM) All evaluable subjects Golimumab vs. Adalimumab
Golimumab Adalimumab N=751 N=751 n (%) n (%) Censored n (%) 343 (45.7) 292 (38.9) Failed n (%) 408 (54.3) 459 (61.1)
Survival time (Months) Median (K-M) 18.4 15.5 95% CI of median (K-M) 15.2 , 24.1 13.1 , 17.1 Q1, Q3 (K-M) 6.0 , NE 5.6 , NE Min , Max 0.2 , 43.2 0.9 , 43.8
KM survival estimates - n at risk, survProb % (95% CI) 1 Month 726, 97 (95-98) 725, 97 (95-98) 3 Months 698, 93 (91-95) 659, 88 (85-90) 6 Months 572, 76 (73-79) 549, 73 (70-76) 12 Months 435, 58 (55-62) 419, 56 (52-59) 18 Months 268, 50 (47-54) 274, 46 (42-49) 24 Months 192, 46 (43-50) 173, 39 (35-43) 30 Months 125, 41 (37-45) 108, 36 (32-39) 36 Months 49, 40 (35-44) 41, 33 (29-37) 42 Months 4, 32 (25-40) 15, 27 (22-34)
NE = Not estimable Testing the equality of the survival function over strata; Log-Rank test – p-value=0.042 First Line Persistence (PSM) All evaluable subjects Golimumab vs. Etanercept
Golimumab Etanercept N=718 N=718 n (%) n (%) Censored n (%) 323 (45.0) 259 (36.1) Failed n (%) 395 (55.0) 459 (63.9)
Survival time (Months) Median (K-M) 17.5 15.2 95% CI of median (K-M) 15.0 , 23.9 13.1 , 16.6 Q1, Q3 (K-M) 6.0 , NE 4.8 , NE Min , Max 0.2 , 43.2 0.5 , 43.7
KM survival estimates - n at risk, survProb % (95% CI) 1 Month 694, 97 (95-98) 678, 94 (92-96) 3 Months 665, 93 (91-94) 602, 84 (81-86) 6 Months 544, 76 (73-79) 500, 70 (66-73) 12 Months 411, 58 (54-61) 404, 57 (53-60) 18 Months 257, 50 (46-54) 266, 44 (40-48) 24 Months 190, 46 (42-50) 170, 37 (33-41) 30 Months 123, 40 (36-44) 110, 33 (29-36) 36 Months 49, 39 (35-43) 42, 29 (25-33) 42 Months 4, 32 (24-40) 10, 25 (19-32)
NE = Not estimable Testing the equality of the survival function over strata; Log-Rank test – p-value=0.006 First Line Persistence (PSM) All evaluable subjects Golimumab vs. Certolizumab Pegol
Golimumab Certolizumab Pegol N=462 N=462 n (%) n (%) Censored n (%) 209 (45.2) 192 (41.6) Failed n (%) 253 (54.8) 270 (58.4)
Survival time (Months) Median (K-M) 16.2 16.1 95% CI of median (K-M) 13.0 , 23.0 13.8 , 20.0 Q1, Q3 (K-M) 6.0 , NE 5.8 , NE Min , Max 1.0 , 43.0 0.9 , 43.0
KM survival estimates - n at risk, survProb % (95% CI) 1 Month 446, 97 (94-98) 449, 97 (95-98) 3 Months 424, 92 (89-94) 421, 91 (88-93) 6 Months 346, 75 (71-79) 342, 74 (70-78) 12 Months 255, 55 (51-60) 264, 58 (53-62) 18 Months 148, 49 (44-53) 167, 48 (43-53) 24 Months 97, 45 (40-50) 98, 40 (36-45) 30 Months 65, 41 (36-46) 50, 36 (31-41) 36 Months 18, 39 (34-45) 22, 32 (26-38) 42 Months 2, 28 (16-42) 4, 25 (16-35)
NE = Not estimable Testing the equality of the survival function over strata; Log-Rank test – p-value=0.634